1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Taiwan Bio Therapeutics Co., Ltd.

Taiwan Bio Therapeutics Co., Ltd.

TTPEX:6892
26.70
TWD
-0.20
(-0.74%)
-4.97EPS
2.81BMarket Cap
Taiwan Bio Therapeutics Co., Ltd.
TPEX:6892
(Taipei Exchange)

Recent

price

26.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
- -
0.91
0.9
1.49
1.44
0.6
1.25
Revenue per Share
-3.7
-3.62
-3.02
-3.78
-3.79
-4.81
-4.51
-4.97
Basic EPS, GAAP
-3.27
-6.35
-7.84
-4.47
-4.98
-4.97
-2.89
-3.67
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.61
1.26
4.82
9.77
9.78
12.87
8.59
10.59
Book Value per Share
0.58
1.26
4.77
9.69
8.76
11.91
3.86
9.78
Tangible Book Value per Share
7
10
30
50
57
73
85
82
Basic Weighted Avg Shares
- -
- -
27
45
85
105
50
102
Sales/Revenue/Turnover
- -
- -
-320.49
-417.14
-251.08
-334.41
-762.04
-385.07
Operating Margin (%)
2
3
29
53
66
99
125
113
Depreciation Expense
-26
-35
-90
-189
-218
-352
-382
-406
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-332.13
-421.41
-254.49
-334.75
-756.85
-396.79
Profit Margin (%)
31
-86
39
248
272
709
277
545
Working Capital
- -
2
274
271
251
286
283
299
LT Debt
32
67
257
527
613
1,091
730
899
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-70.49
-55.73
-48.14
-38.16
-41.27
-41.92
-45.53
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
31
31
31
LT Borrowings
- -
- -
- -
LT Finance Leases
286
306
299
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
85
85
85
Market Capitalization
3,535
2,931
2,809

Working Capital

TWD

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
786
704
622
Cash, Cash Equivalents & STI
678
588
530
Accounts Receivable, Net
39
36
9
Inventories
31
35
37
Total Current Liabilities
77
70
76
Payables & Accruals
- -
- -
- -
ST Debt
31
31
31
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
89.68%
-33.15%
Free Cash Flow
- -
59.66%
-32.71%
Net Income, GAAP
- -
70.41%
8.48%
Sales/Revenue/Turnover
- -
- -
-52.02%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
105
2025
- -
- -
50
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-4.81
2025
- -
- -
-4.51
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Taiwan Bio Therapeutics Co., Ltd. (TPEX:6892) develops and manufactures advanced cell therapy products for regenerative medicine, focusing on degenerative diseases, cardiovascular conditions, diabetes complications, and autoimmune disorders; its core offerings include allogeneic stem cell drugs such as Biochymal for critical limb ischemia, Chondrochymal for knee osteoarthritis, OmniMSC-AMI for acute myocardial infarction, and genetically modified mesenchymal stem cells (MSCs) like bone marrow-derived MSCs and MSC-VEGF, alongside CDMO services via its Therapeutics Design & Manufacturing (TDM) model that supports preclinical and early clinical-stage cell therapies from R&D to production. The company leverages its proprietary FAST CGT platform, integrating big data analytics, transgene design, cell engineering, gene modification, and automated manufacturing to enhance efficacy, reduce costs, and accelerate development. Founded in 2014 and headquartered in Taipei City, Taiwan, with facilities in Hsinchu County and a U.S. subsidiary, Taiwan Bio Therapeutics operates primarily in Asia while expanding globally through collaborations with U.S. universities and institutions, targeting chronic and immune-related diseases. In August 2025, the company acquired U.S.-based TRACT Therapeutics, Inc., bolstering its leadership in regulatory T cell (Treg) therapies for organ transplantation and autoimmune diseases, following a 2023 strategic partnership and successful technology transfer of TRACT's TregCel platform to its GMP facility in preparation for a global Phase 2 trial in kidney transplant patients.